Matthew Rabinowitz, Co-Founder of Natera
Top builders in biotech
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you — email us at info@axialvc.com
Matthew Rabinowitz is the Co-Founder, Executive Chairman, and former CEO of Natera. A genetic testing company pioneering cell-free DNA diagnostics for women’s health, oncology, and organ health. While completing his PhD dissertation, Rabinowitz co-founded an Panop.com, an online merchandising company, in 1998. Selling the company for $100M. In 2000, he founded Rosum to develop location technology to augment GPS.
Rabinowitz was motivated to start Natera after a family member’s child passed away in infancy. Founded in 2004, originally called Gene Security Network, with Jonathan Sheena, Natera’s launch its first product in 2009, Spectrum, a preimplantation test for IVF. Then launching Anora, a miscarriage test in 2010. And Horizon, an advanced carrier screening test in 2012.
In 2013, launching their flagship product, Panorama. A non-invasive prenatal test (NIPT) to screen for common chromosomal conditions. Analyzing fetal DNA in the mother’s blood for genetic disorders like Down & Edwards syndrome. With this traction, Natera went public through an IPO in 2015. Successively launching more products in prenatal/women’s health and expanding into oncology. Launching Vistara, as a higher coverage NIPT for 25 genetic disorders.
Getting into oncology with Signatera, as a CLIA test to monitor molecular residual disease (MRD) and cancer recurrence. And into organ health with Prospera; a cfDNA test to assess kidney transplant rejection (both T-cell and antibody-mediated rejection). And Renasight in 2020 for kidney disease and Empower for hereditary cancer (up to 53 genes). Supporting a business generating well over $700M in annual revenue performing 100Ks of tests & millions in total.
Now Rabinowitz, is the Co-Founder and Chairman of MyOme. To develop whole-genome sequencing diagnostics to help IVF with embryo selection and generating/evaluating polygenic risk scores for cancer, autoimmune, cardiovascular, metabolic, and cognitive conditions.